China Resources Jiangzhong Pharmaceutical, with stock code 03320, reported a net profit attributable to parent of 907 million yuan in 2025, representing a year-on-year growth of 15.03%.

18:19 19/03/2026

China Resources Medicine (03320) announced the annual performance of China Resources Jiangzhong Pharmaceutical Co., Ltd. (China Resources Jiangzhong) as of December 31, 2025. The total revenue was 4.22 billion yuan, a decrease of 4.87% compared to the previous year, and the net profit attributable to the shareholders of the listed company was 907 million yuan, an increase of 15.03% year-on-year. Earnings per share were 1.43 yuan. It is proposed to distribute a cash dividend of 8.80 yuan (tax included) for every 10 shares.

CHINARES PHARMA (03320) released the annual performance of China Resources Jiangzhong Pharmaceutical Co., Ltd. (China Resources Jiangzhong Pharmaceutical) as of December 31, 2025. The company's total revenue was 4.22 billion RMB, a decrease of 4.87% year-on-year, and the net profit attributable to shareholders of the listed company was 907 million RMB, an increase of 15.03% year-on-year. Earnings per share were 1.43 RMB. It is proposed to distribute a cash dividend of 8.80 RMB (tax included) for every 10 shares.

Wellington Management Group LLP increased its holdings of GENFLEET-B (02595) by 2.5242 million shares, with an approximate price per share of around 27.26 Hong Kong dollars.

Silchester International Investors LLP increased its holding in YUE YUEN IND (00551) by 1.31 million shares at a price of approximately HK$15.94 per share.

EPI (HOLDINGS) (00689) granted a loan facility of NZD 3 million.

Wellington Management Group LLP increased its holdings of GENFLEET-B (02595) by 2.5242 million shares, with an approximate price per share of around 27.26 Hong Kong dollars.

Silchester International Investors LLP increased its holding in YUE YUEN IND (00551) by 1.31 million shares at a price of approximately HK$15.94 per share.

EPI (HOLDINGS) (00689) granted a loan facility of NZD 3 million.